Status Plus




The impact of liraglutide treatment on the erectile function of the diabetic rats

Gonultas, S1; Tuken, M1; Culha, M.G2; Tavukcu, H.H3; Serefoglu, E.C4; Semercioz, A1

1: Bagcilar Training & Research Hospital,Urology Department, Istanbul, Turkey; 2: Okmeydani Training & Research Hospital,Urology Department, Istanbul, Turkey; 3: Florence Nightingale Hospital,Urology Department, Istanbul, Turkey; 4: Uroklinik - Center of Excellence in Urology, Istanbul, Turkey

Objectives: Glucagon-like peptide-1 (GLP-1) is a peptide hormone released from intestinal L cells following nutrient consumption. It potentiates secretion of insulin from pancreatic beta cells thus GLP-1 analogues are used fort he treatment of type 2 diabetes (T2D). The aim of this study is to evaluate the impact of GLP-1 receptor agonist liraglutide on the erectile function of the diabetic rats.

Material and Methods: A total of 30 male Sprague-Dawley rats (13 weeks old, 240-335 gr) were fed with fatty diet for 2 weeks. The rats were divided into 3 groups (n=10 each). The rats in the first group served as controls (group C) whereas the rats in the remaining two groups were injected with streptozosin and became T2D for forming diabetic group (group D) and treatment group (group T). Rats in group D received citrate buffer injections whereas rats in the group T received liraglutide injections (0.3mg/kg/12h) subcutaneously. Erectile functions of all rats were evaluated with intracavernosal pressure (ICP)/mean arterial pressure (MAP) measurements. Moreover, sex hormone levels (Testosteron, FSH, LH) were evaluated and histological assessment of the midpenile tissue were performed (Collagen Type IV, rat epithelial antigen 1, nNOS).

Results: Maximum ICP/MAP ratios were 79.127 ± 16.259, 26.3 ± 13.912 and 65.175 ± 13.141 in groups C, D and T. Although mean ICP/MAP ratios were similar in groups C and T (p=0,135), mean ICP/MAP ratio was significantly lower in group D (p<0.001). Histological analyses revealed that nNOS (p<0,001) rat epithelial antigen 1 (RECA-1) (p=0.08) and muscle/collagen ratio (p<0.05) were also lower compared with the other groups. Testosteron, FSH and LH results were significantly lower in the group D (p=0.12).

Conclusions: GLP-1 receptor agonist liraglutide demonstrated protective effects on the erectile tissues of the diabetic rats. Clinical trials are required to confirm if liraglutide treatment has similar beneficial effects on men who have T2D.


Work supported by industry: no.

Go Back